BridgeBio Pharma Stock Jumps 16% on BofA Surprise Over Heart Drug Trial Failure
BBIO•BridgeBio Pharma shares rose 16% after Bank of America flagged the unexpected failure of the AstraZeneca-Ionis heart drug trial to meet its primary endpoint. The surprise negative readout triggered a sector rotation into BridgeBio’s pipeline-focused biotech profile.
1. Shares Rally on Trial News
BridgeBio Pharma stock surged 16% in early trading after disclosure that the AstraZeneca-Ionis cardiovascular candidate failed to achieve its primary endpoint. This marked the company’s biggest one-day gain in over a year as investors reallocated funds within the biotech sector.
2. BofA Labels Outcome ‘Big Surprise’
Bank of America analysts described the trial miss as a ‘big surprise’, having forecast higher efficacy for the heart failure drug. The firm noted that the setback could prompt a reshuffle of small-cap biotech allocations.
3. Sector Rotation and Peer Moves
The trial’s negative readout weighed on AstraZeneca and Ionis shares, each sliding around 8%, while peers such as Alnylam and Pfizer saw modest upticks. Market participants rotated into BridgeBio Pharma for its diversified pipeline and upcoming data milestones.
